Histopathology of hemangiopericytoma, solitary fibrous tumor and meningiomas (H&E).

<p>Representative cases of selected hemangiopericytoma (A), solitary fibrous tumor (B), and, atypical (C), anaplastic (D), meningothelial (E), angiomatous (F), and fibrous (G) meningioma. Solitary fibrous tumors (A) and hemangiopericytomas (B) are occasionally difficult to distinguish from high-grade meningiomas (C, D).</p

Fraction of immunoreactive cells to Slug, Twist, E-cadherin, and N-cadherin in meningeal tumors.

<p>The number of Slug-, Twist-, E-cadherin-, and N-cadherin-positive cells in immunohistochemistry was estimated using a four-tiered scale; -, <10%; +, 10-49%; ++, 50-90%; +++, >90%.</p

Kaplan-Meier estimates of overall survival.

<p>P-values were calculated using a two-sided log-rank test. TMZ, temozolomide.</p

Kaplan-Meier estimates of overall survival in TMZ-treated patients with high and low MIB-1 LI.

<p>Cut-off value for MIB-1 LI was set at 23%. P-values were calculated using a two-sided log-rank test.</p

Characteristics of patients treated with radiotherapy plus temozolomide.

<p>CTR, control group; TMZ, temozolomide group; GTR, gross total removal; SR, subtotal removal; PR, partial removal; MGMT, O6-methylguanine DNA metyltransferase; BED, biological effective dose; SD, standard deviation; IFN-β, interferon-β. MIB-1 labeling index could not be assessed in one patient because of insufficient paraffin-embedded tissue.</p

Kaplan-Meier estimates of overall survival.

<p>Values with 95% confidence interval are shown. CTR, control group; TMZ, temozolomide group.</p

Univariate and multivariate analysis for survival in the TMZ group.

†<p>Potential prognostic factors of which P-value was calculated as <0.15 were evaluated by multivariate analysis using stepwise method. TMZ, temozolomide; GTR, gross total removal; SR, subtotal removal; PR, partial removal; BED, biological effective dose; IFN-β, interferon-β; MGMT, O6-methylguanine DNA metyltransferase.</p

Grade 3 or 4 hematologic toxicity in patients treated with temozolomide.

<p>Hematologic toxic effects were evaluated by Common Terminology Criteria for Adverse Events v4.0.</p